Cargando…

What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs

BACKGROUND: Communicating risk is difficult. Although different methods have been proposed – using numbers, words, pictures or combinations – none has been extensively tested. We used electronic and bibliographic searches to review evidence concerning risk perception and presentation. People tend to...

Descripción completa

Detalles Bibliográficos
Autores principales: Moore, R Andrew, Derry, Sheena, McQuay, Henry J, Paling, John
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374447/
https://www.ncbi.nlm.nih.gov/pubmed/18257914
http://dx.doi.org/10.1186/ar2373
_version_ 1782154455825776640
author Moore, R Andrew
Derry, Sheena
McQuay, Henry J
Paling, John
author_facet Moore, R Andrew
Derry, Sheena
McQuay, Henry J
Paling, John
author_sort Moore, R Andrew
collection PubMed
description BACKGROUND: Communicating risk is difficult. Although different methods have been proposed – using numbers, words, pictures or combinations – none has been extensively tested. We used electronic and bibliographic searches to review evidence concerning risk perception and presentation. People tend to underestimate common risk and overestimate rare risk; they respond to risks primarily on the basis of emotion rather than facts, seem to be risk averse when faced with medical interventions, and want information on even the rarest of adverse events. METHODS: We identified observational studies (primarily in the form of meta-analyses) with information on individual non-steroidal anti-inflammatory drug (NSAID) or selective cyclooxygenase-2 inhibitor (coxib) use and relative risk of gastrointestinal bleed or cardiovascular event, the background rate of events in the absence of NSAID or coxib, and the likelihood of death from an event. Using this information we present the outcome of additional risk of death from gastrointestinal bleed and cardiovascular event for individual NSAIDs and coxibs alongside information about death from other causes in a series of perspective scales. RESULTS: The literature on communicating risk to patients is limited. There are problems with literacy, numeracy and the human tendency to overestimate rare risk and underestimate common risk. There is inconsistency in how people translate between numbers and words. We present a method of communicating information about serious risks using the common outcome of death, using pictures, numbers and words, and contextualising the information. The use of this method for gastrointestinal and cardiovascular harm with NSAIDs and coxibs shows differences between individual NSAIDs and coxibs. CONCLUSION: Although contextualised risk information can be provided on two possible adverse events, many other possible adverse events with potential serious consequences were omitted. Patients and professionals want much information about risks of medical interventions but we do not know how best to meet expectations. The impact of contextualised information remains to be tested.
format Text
id pubmed-2374447
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-23744472008-05-09 What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs Moore, R Andrew Derry, Sheena McQuay, Henry J Paling, John Arthritis Res Ther Research Article BACKGROUND: Communicating risk is difficult. Although different methods have been proposed – using numbers, words, pictures or combinations – none has been extensively tested. We used electronic and bibliographic searches to review evidence concerning risk perception and presentation. People tend to underestimate common risk and overestimate rare risk; they respond to risks primarily on the basis of emotion rather than facts, seem to be risk averse when faced with medical interventions, and want information on even the rarest of adverse events. METHODS: We identified observational studies (primarily in the form of meta-analyses) with information on individual non-steroidal anti-inflammatory drug (NSAID) or selective cyclooxygenase-2 inhibitor (coxib) use and relative risk of gastrointestinal bleed or cardiovascular event, the background rate of events in the absence of NSAID or coxib, and the likelihood of death from an event. Using this information we present the outcome of additional risk of death from gastrointestinal bleed and cardiovascular event for individual NSAIDs and coxibs alongside information about death from other causes in a series of perspective scales. RESULTS: The literature on communicating risk to patients is limited. There are problems with literacy, numeracy and the human tendency to overestimate rare risk and underestimate common risk. There is inconsistency in how people translate between numbers and words. We present a method of communicating information about serious risks using the common outcome of death, using pictures, numbers and words, and contextualising the information. The use of this method for gastrointestinal and cardiovascular harm with NSAIDs and coxibs shows differences between individual NSAIDs and coxibs. CONCLUSION: Although contextualised risk information can be provided on two possible adverse events, many other possible adverse events with potential serious consequences were omitted. Patients and professionals want much information about risks of medical interventions but we do not know how best to meet expectations. The impact of contextualised information remains to be tested. BioMed Central 2008 2008-02-07 /pmc/articles/PMC2374447/ /pubmed/18257914 http://dx.doi.org/10.1186/ar2373 Text en Copyright © 2008 Moore et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Moore, R Andrew
Derry, Sheena
McQuay, Henry J
Paling, John
What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs
title What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs
title_full What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs
title_fullStr What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs
title_full_unstemmed What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs
title_short What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs
title_sort what do we know about communicating risk? a brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective nsaids
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374447/
https://www.ncbi.nlm.nih.gov/pubmed/18257914
http://dx.doi.org/10.1186/ar2373
work_keys_str_mv AT moorerandrew whatdoweknowaboutcommunicatingriskabriefreviewandsuggestionforcontextualisingseriousbutrareriskandtheexampleofcox2selectiveandnonselectivensaids
AT derrysheena whatdoweknowaboutcommunicatingriskabriefreviewandsuggestionforcontextualisingseriousbutrareriskandtheexampleofcox2selectiveandnonselectivensaids
AT mcquayhenryj whatdoweknowaboutcommunicatingriskabriefreviewandsuggestionforcontextualisingseriousbutrareriskandtheexampleofcox2selectiveandnonselectivensaids
AT palingjohn whatdoweknowaboutcommunicatingriskabriefreviewandsuggestionforcontextualisingseriousbutrareriskandtheexampleofcox2selectiveandnonselectivensaids